PhRMA opposes proposed rule on US Medicare Advantage & Part D

20 February 2014

Pharmaceutical Research and Manufacturers of America (PhRMA) stated yesterday that it is opposed to the proposed rule on Medicare Advantage and Part D that CMS released in early January because it could disrupt care for millions of beneficiaries.

The Part D program is already working well, making the proposed rule unnecessary and harmful. Quite simply, it is a solution in search of a problem, says PHRMA senior vice president Matthew Bennett, adding: “Since 2006, the Part D program has developed a strong track record of success. Currently, total Part D costs are 45% - or $348 billion - lower than initial projections for 2004-2013. Additionally, average beneficiary premiums are stable at $31 per month in 2014 - less than half the level originally projected. And several surveys have found that 90% or more of Part D beneficiaries are satisfied with their coverage.”

Would unlawfully interfere in a competitive, market-based program that is working

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK